IMUNON to Hold First Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, May 12, 2026
IMUNON, Inc., a clinical-stage biotech developing DNA-mediated immunotherapies, announced its Q1 2026 financial results and business update conference call set for May 12, 2026. The company will provide updates on IMNN-001, its lead DNA-based interleukin-12 immunotherapy in Phase 3 trials for advanced ovarian cancer, and report progress on its clin…